Therefore, MDM2 represents a promising therapeutic target for alleviating I/R-induced AKI, and drugs targeting MDM2 that promote MDM2 expression and subsequently inhibit p53 may effectively ameliorate renal ischemia–reperfusion injury. Here, TP53 is linked to acute kidney injury.